$0.01▴ 28.57%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-101.55MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-4.3%year over year
Weak
Revenue is contracting year over year.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
✦ The read
Humacyte, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year. Elevated leverage worth keeping an eye on.
Key numbers
Valuation
EPS (TTM)$-0.59
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-4840.8%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$2.02M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.